SciLifeLab (Science for Life Laboratory) is Sweden’s national center for molecular biosciences, with the mission to provide a unique and enabling infrastructure to the life science community, facilitate internationally leading collaborative science, and promote the translation of biomolecular research findings into lasting societal benefits.
As part of the Nordic Life Science Days 2018, we invite you to attend a one-day satellite symposium to learn more about SciLifeLab, meet our facilities, investigate our capabilities and technologies, and further develop how your organization can leverage this unique asset in Sweden’s life science sector.
The symposium is free of charge and exclusive for registered participants of NLSDays. If you have not yet registered for NLSDays, please visit www.nlsdays.com. The event is held in Aula Medica at Karolinska Institutet on Monday 10 September 2018, between 10:00–15:00. Bus service round trip from Stockholm Waterfront will be provided.
Welcome to sign up now at:
Location: GE Healthcare Life Sciences’ site, Björkgatan 30, Uppsala
Date and time: Monday, 10 September, 2018
During the past years, we have been witnessing tremendous growth in the biopharmaceutical sector; bio-drugs are now the world’s fastest-growing class of medicines.
GE Healthcare Life Sciences develops and manufactures both the equipment and supplies to manufacture biopharmaceuticals, and today all ten top biologic drugs in the market use GE technologies in their manufacturing processes.
We are inviting you to visit GE Healthcare Life Sciences’ site in Uppsala that employs around 1,200 people, covering production, research & development and business support services. The factory in Uppsala is one of the largest manufacturing facilities for chromatography resins in the world, and between 2017 and 2022 GE is annually investing up to USD 70 million to increase the production capacity.
In August opens Testa Center in Uppsala, a major initiative between the Swedish government and GE to secure the growth of the nation’s life science industry and its manufacturing capabilities in particular. This facility is purpose-built for verifying digital, technical or biological innovations in an authentic production setting and open to academia, start-ups and industry.
Join us for an afternoon to experience this exciting and innovative life sciences site that helps to increase access to biopharmaceuticals globally.
11.45 Bus transfer from Waterfront Conference Center to GE Healthcare Life Sciences’ Site Uppsala
12:30-13.00 Registration and coffee in GE Healthcare Life Sciences Reception Area
13.00-13:30 Opening remarks & Welcome: Lotta Ljungqvist, President & CEO GE Nordics and CEO Testa Center
13.30-16.00 Guided tours in the manufacturing facilities and the newly opened Testa Center
14.30-15.00 Coffee break in Reception Area
16:00 Closing remarks
16:30 Bus transfer from GE Healthcare Life Sciences´ site to Waterfront Conference Center
Opened to NLSDays’ participants only!
Interested in joining?
Please sign up for free by sending an email to email@example.com with the following details:
Academia is a key engine for medical innovation and many life science projects becoming commercial successful originate from academic centers. Big ideas very often come from ground-braking academic research. Recognizing that majority of the global companies made academic-industrial partnerships an integral part of their strategies and opened their R&D organizations to external innovation.
The Academic Catwalk features exciting academic projects from three Nordic countries illustrating the rich and broad research milieus and their motivation to advance their ideas into innovations for patients. The session is hosted by SPARK Norway (www.uio.no/life-science/spark) in collaboration with the European Partners SPARK Finland and SPARK Berlin and supported by Karolinska Innovation.
Moderator: Prof. Craig Garner - Berlin Institute of Health, Founder SPARK Berlin
Dr. Gunnveig Grødeland - Project Leader, UiO, Spark Norway Dr. Magnus Aronsen - Project Leader, UiO, Spark Norway Mr. Jonas Skogestad - Project Leader, UiO, Spark Norway Prof. Klaus Hedman - Project Leader, University of Helsinki, Spark Finland Dr. Ulla Aapola - Project Leader, University of Tampere, Spark Finland Prof. Per Hall - Professor, Karolinska Institutet Dr. Ylva Trolle Lagerros - Associate Professor, Karolinska Institutet
Startup Challenge is an enjoyable pitching event showcasing the best and brightest startups currently emerging from the nordic life science ecosystem. Based on their video contributions, the best 12 will be selected to pitch live in front of life science industry decision makers and investors. It means that they will be pitching in front of a qualified audience.
Game Intelligence AB
Gedea Biotech AB
Quantum Leap Computing Labs
Sigrid Therapeutics AB
Stayble Therapeutics AB
Tirmed Pharma AB
Moderator: Ms. Carolina Hawranek - Head of PR and Communications, Umeå Biotech Incubator
Starting and evolving a company requires funds. This session is aimed at helping you better navigate the jungle of financing. We will take you through inspiring journeys that will be discussed by an experienced panel of investors, from Business Angels to Venture Capital firms.
Mr. Nicolaj Sörensen - CEO & President, Orexo Mr. Anders Martin-Löf - CFO, Wilson Therapeutics Dr. Sonia Benhamida - Senior Vice President Healthcare, DNB Dr. Øyvind Kongstun-Arnesen - CEO, Ultimovacs Mr. Jacob Guntherberg - Partner, HealthCap Mr. Stephan Christgau - Senio Partner, Novo Seeds Dr. Patrik Sobocki - Investment Manager, Industrifonden Mr. Kim Baden-Kristensen - Founder & CEO, Brain+
Patient engagement in very much in vogue, but does it really make a difference and how can we measure this? This session will look at what patient engagement actually means in practical terms, and its impact as a business development tool, drawing on concrete good practice examples from the rare diseases community and personalised medicines.
We will also explore
Moderator: Ms. Nicola Bedlington - Secretary General, European Patients' Forum
Dr. Markku Toivonen - Scientific Director, NDA Group Dr. Ana Palma - Senior Director Global HTA & Patient Access Lead, Sobi
Visionary companies exploiting nano-features to boost pharma- and medical device products. Scientific, financial and commercial perspectives of nanomedicine will be covered.
Moderator: Mr. Patrick Boisseau - Programme Manager on Nanomedicine, CEA-Leti
Dr. Filippo Bosco - Founder & CEO, BluSense Diagnostics Dr. Agneta Richter-Dahlfors - CEO, EBBA Biotech Mr. Kristian Thulin - CSO, Obducat Technologies Dr. Mats Hansen - CEO, Spago Nanomedical Mr. Magnus Larsson - CEO, Promimic Dr. Maureen Deehan - Head of Corporate Development & Strategy, Nordic Nanovector
Technology gives access to a wealth of data and enables personalized care in an increasingly connected world. Future innovation in life science is about integrating medtech, pharmaceuticals and digital solutions. It requires innovative thinking in many dimensions.
How can we increase cooperation to integrate these areas more?
The regulatory requirements within pharma are challenging. The crusial question is how to handle the rapid development and take advantage of digital health solutions.
Moderator: Dr. Magnus Björsne - CEO, , AstraZeneca BioVentureHub
Dr. Sara Lei - Clinical Advisor, Karolinska University Hospital Mr. Magnus Jörntén-Karlsson - Project Director, AstraZeneca R&D Dr. Ingrid Teigland Akay - Managing Partner, Hadean Ventures Ms. Jennifer Grönqvist - Business Advisor HealthTech Nordic, SSP
Many SME companies focused on drug development choose to work according a virtual business model where key expertise is contracted ad hoc for specific tasks. Often also more general tasks such as project management may be covered by contracted staff. The virtual model is attractive because it adds flexibility and supports the agile organization. On the other hand, working virtually requires additional care when considering what tasks to outsource and criteria for selection of vendors.
The session “The Virtual Business Model” will focus on “WHY”, “WHEN” and “HOW” from a company management perspective. When will virtual competence add the extra edge are there situation when the virtual model is not advantageous?
The speaker list includes speakers experienced in working in a virtual business model as well as companies supplying virtual services.
Moderator: Dr. Anna Törner - Managing Director, Scandinavian Development Services
Opportunities within precision and personalized medicine attracts much interest, not only from scientists, drug markers and patients but also from funders and decision makers.
Alongside opportunities, however, there are also several challenges to overcome to ensure successful launch and implementation of truly personalized therapies.
The changes required for drug manufacturers, healthcare providers and payers are radical and transformative, and involves the full value chain with all its stakeholders.
This session will talk about what it will really take from the healthcare ecosystem players when preparing for taking full advantage of the promising new precision treatments currently being developed in many important disease areas.
Moderator: Dr. Ulrica Sehlstedt - Partner, Arthur D. Little
Dr. Sara Gunnerås - Diector EU Support Office, SwedenBIO Dr. Ann Atlas - Senior Scientific Advisor I-O and HCV, BMS Dr. Johan Botling - Researcher, Uppsala University Mr. Craig Wylie - Partner, Arthur D. Little
Drug delivery is the science of getting the right amount of active drug to the right place in the body at the right time. The area of drug delivery has increased in importance as the medical needs continuously present new challenges to us and new and more complex treatment modalities are developed. In some of these modalities the drug delivery system and the active pharmaceutical ingredient (API) will be integrated to form the therapy and need to be fully aligned. Furthermore, challenges such as patient adherence, paediatrics/geriatrics and personalized medicine present challenges where innovative drug delivery solutions can add huge value to patients and society.
In this session, we will have presentations from three ongoing research initiatives related to advanced drug delivery: Sweden Drug Delivery Forum, NextBioForm and FoRmulaEx. We will also get a brief introduction to the industry network Sweden Drug Delivery Industry Group and get some messages from the sponsors of this session. Finally, a short panel discussion with the presenters discussing the future challenges and new opportunities will finish off the session.
Moderator: Dr. Eva Sjökvist-Saers - CEO & Managing Director, APL
Prof. Marie Wahlgren - Deputy Head, Department of Food Technology, Lund University Dr. Christel Bergström - Associate Professor, Uppsala University Dr. Elin Esbjörner-Winters - Associate Professor, Biophysical Chemistry and Biochemistry, Chalmers University
The Innovative Medicines Initiative (IMI) is a partnership between the European Union and the European Pharmaceutical Industry. IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalized medicines for the health and wellbeing of all, especially in areas of unmet medical need.
Moderator: Dr. Gunnar Sandberg - Program Director, Vinnova
Ms. Magda Chlebus - Director Science Policy, EFPIA Dr. Colm Carrol - Scientific Project Manager, IMI Joint Undertaking Prof. Mikael Kubista - CEO and Founder, ATAA BioCenter Dr. Bertil Abrahamsson - Senior Principal Scientist, AstraZeneca
Given you sometimes only get one chance to tell your story right, its essential that pitch it appropriately to investors. This session will provide an opportunity to hear from leading life science investors to better understand their areas of interest and investment criteria and what they would like to hear from you.
The pitching session will be followed by an interactive QA session to provide the audience with an opportunity to ask questions.
Moderator: Ms. Katja Stout - Managing Director, Scius Communications Mr. Hans Herklots - Managing Director, LifeSci Advisors
Dr. Ingrid Teigland Akay - Managing Partner, Hadean Ventures
This Super Session gathers top experts from the pharmaceutical and private fertility industry who will discuss the business and the industries perspective on reproductive medicine.
Every 12th child is conceived in a fertility clinic. 16-25 % of couples that try to get pregnant have fertility problems. The birth rate has fallen drastically over the past 50 years and most countries have fertility rate of less than 1,5 children per woman. The combination of demographic development and the low fertility rates demands new solutions and services. This development creates new business opportunities for the private fertility sector.
This session is hosted by ReproUnion – _a cross border collaboration between Sweden and Denmark within the area of reproductive medicine. The collaborative network consists of 14 clinical and research units within the Capital Region of Denmark, Region Zealand of Denmark and Region Skåne in Southern Sweden.
Dr. Stig Jørgensen - Program Director ReproUnion Dr. Rita Vassena - Scientific Director, Eugin, Executive Member of ESHRE Dr. Marcel Van Duin - VP, Head Reproductive Health & Endocrinology Research, Ferring Pharmaceuticals, Ferring Pharmaceuticals
At this session, international experts from pharma, biotech, academia and the investment community will discuss how big data, personalized medicine, beyond the pill approaches, new targets, an increased understanding of the microbiome and insights from neuroscience could address these challenges and shape the next wave of innovation in Immuno-Oncology (I-O).
Over the past few years, the rapid development of novel cancer immunotherapy approaches has fundamentally disrupted the oncology space. I-O has not only become a key component of cancer therapy, but it has also reshaped priorities in oncology R&D across the industry, with unprecedented clinical success in certain cancer types continuing to fuel record investment and partnering activity. As of today, more than 2.000 I-O agents, including checkpoint-inhibitors, vaccines, oncolytic viruses and cellular therapies, are in preclinical or clinical development
Yet, still only a minority of patients benefits from effective and durable I-O treatments. Beyond resistance or unexplained lack of response, which could be addressed through a better understanding of optimal timing of therapy, better combination therapy design, or improved patient selection, a lack of novel targets and of an overall better understanding of specific immune mechanisms is becoming a roadblock to further advance in the space.
Moderator: Dr. Gaspar Taroncher-Oldenburg - Editor-at-Large, Nature Publishing Group
Dr. Richa Wilson - Associate Director, Digital and Personalized Healthcare, Roche Partnering Dr. Emilio Erazo-Fischer - Associate Director of Global Oncology BD, Boehringer Ingelheim Dr. Simon Skjøde Jensen - CEO and Co-Founder, MonTa Biosciences Dr. Martin Bonde - CEO, Vaccibody Dr. Erica Sloan - Group Leader, Cancer & Neural-Immune Research Lab, Monash University Mr. Peter Benson - Co-founder and Managing Partner, Sunstone Life Science Ventures
Technological advancements in molecular life science are evolving at an ever-increasing rate. As we move towards greater integration of large-scale omics into both preclinical and clinical settings, novel and complementary methods for detection, characterization, and diagnosis of disease states at highresolution and -throughput are emerging. At SciLifeLab, development and application of new tools for life science are a core component of our mission. In this workshop, we will present four innovative technologies we make available to the Swedish research community and interactively discuss their use and application.
How will the development of these and other emerging technologies help shape the future of healthcare, drug discovery and diagnostics? How do we secure transfer of knowledge and development of new technologies towards applications in healthcare and the private sector? In what way can SciLifeLab best support the life science research community in Sweden through collaboration and service?
Moderator: Dr. Lars G.J. Hammarström - Strategic Relations Officer, SciLifeLab
Dr. Annika Jenmalm-Jensen - Infrastructure Director, SciLifeLab Prof. Gunnar Von Heljne - Facility Director, SciLifeLab Dr. Petter Brodin - Facility Director, SciLifeLab Prof. Ulf Landegren - Facility Director, SciLifeLab Prof. Joakim Lundeberg - Facility Director, SciLifeLab
This workshop takes a practical stand on how, when and why management of Intellectual Property will play a decisive role in the development of a Life Science business. There is no “one size fits all” when working out a business plan, and consequently there is not one ready-made solution for managing intellectual protection of your invention, business plan and trade dress. During this session, you will hear how experts in the fields of Life Science and Intellectual Property have successfully handled different business challenges with the use of intellectual property tools, to achieve the most suitable and profitable return on investment.
On stage, you will meet European Patent Attorney Niklas Mattsson (AWA) and Attorney at Law Louise Jonshammar (AWA), CEO Ebba Fåhraeus (Smile Incubator) and CEO David Bejker (Affibody). You will also get insights into other Life Science companies’ work with IP related to their inventions and discoveries, such as Sprint Bioscience.
Moderator: Ms. Sandra Lindvall - Patent Attorney, Awapatent
Ms. Louise Jonshammar - Attorney At Law, Awapatent Mr. Niklas Mattsson - Partner and European Patent Attorney, Awapatent Ms. Johanna Berg - Partner and European Patent Attorney, AWA
The fast growing amount of biobank and health data presents an unparalled opportunity for drug target and biomarker discovery, Real Worl Evidence-based research (RWE) and personalized healthcare.
However, this opportunity presents also a challenge on how to make sense of this data and find medically meaningful discoveries.
The application of artificial intelligence (AI) solutions may provide one answer to this medical needle in a hay stack problem and help us conquer the burder of common diseases such as diabetes, cancer and neurological diseases.
Prof. Mark Daly - Director, Institute for Molecular Medicine Finland (FIMM) Dr. Minna Hendolin - Senior Director Health & Wellbeing, Business Finland Dr. Visa Honkanen - Director Strategic Development, Helsinki University Hospital Ms. Christina Busmalis - Director, Global Life Sciences at IBM Watson Health